- Home
- HBNC vs ABVX Comparison
HBNC vs ABVX Comparison
Compare HBNC & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HBNC
- ABVX
- Stock Information
- Founded
- HBNC 1873
- ABVX 2013
- Country
- HBNC United States
- ABVX France
- Employees
- HBNC N/A
- ABVX N/A
- Industry
- HBNC Major Banks
- ABVX
- Sector
- HBNC Finance
- ABVX
- Exchange
- HBNC Nasdaq
- ABVX Nasdaq
- Market Cap
- HBNC 692.0M
- ABVX 722.3M
- IPO Year
- HBNC N/A
- ABVX N/A
- Fundamental
- Price
- HBNC $16.77
- ABVX $8.08
- Analyst Decision
- HBNC Hold
- ABVX Strong Buy
- Analyst Count
- HBNC 2
- ABVX 7
- Target Price
- HBNC $19.00
- ABVX $37.86
- AVG Volume (30 Days)
- HBNC 142.3K
- ABVX 162.1K
- Earning Date
- HBNC 01-22-2025
- ABVX 03-24-2025
- Dividend Yield
- HBNC 3.75%
- ABVX N/A
- EPS Growth
- HBNC N/A
- ABVX N/A
- EPS
- HBNC 0.48
- ABVX N/A
- Revenue
- HBNC $183,718,000.00
- ABVX $9,676,417.00
- Revenue This Year
- HBNC N/A
- ABVX $31.67
- Revenue Next Year
- HBNC $18.53
- ABVX $759.77
- P/E Ratio
- HBNC $35.22
- ABVX N/A
- Revenue Growth
- HBNC N/A
- ABVX 100.87
- 52 Week Low
- HBNC $11.18
- ABVX $5.50
- 52 Week High
- HBNC $19.18
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- HBNC 47.21
- ABVX 75.42
- Support Level
- HBNC $16.49
- ABVX $5.88
- Resistance Level
- HBNC $17.62
- ABVX $7.57
- Average True Range (ATR)
- HBNC 0.64
- ABVX 0.46
- MACD
- HBNC -0.05
- ABVX 0.24
- Stochastic Oscillator
- HBNC 38.51
- ABVX 97.68
About HBNC Horizon Bancorp Inc.
Horizon Bancorp (IN) is a United States-based holding company providing banking services. It is engaged in providing commercial and retail banking services, corporate and individual trust and agency services, and other services incident to banking. The company also provides commercial loans, real estate loans, mortgage warehouse loans, consumer loans, and other credit facilities. The company has one principal business segment, commercial banking.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.